

# National Health Basket

- The Healthcare Basket is updated annually
- Yearly health basket budget counts about \$150M (500M NIS), exact budget is approved separately each year
- About 800–850 dossiers are submitted to the health basket each year
- Approximately 8–12% of all the applications gain reimbursement each year
- Therapies that have been approved do not require re-approval the following years
- Therapies that have not been approved can be submitted again in the following years

## The Reimbursement Process – a Full Year Process



\*The public committee consists of members from various fields: Members of the health system – MoH, health funds and hospital; Representatives of the Ministry of Finance; Public representatives including: Specialist (MD), Ethic experts, economics, welfare and other fields. This structure of the basket committee, which includes both medical professionals and health system personnel, as well as public representatives from different and varied fields, was established in order to ensure that the committee's decisions are made from an overall social-public perspective, paying attention to various public aspects related to the complex issue before the committee, and this alongside a point The professional medical view and considering the resources allocated by the government to the health basket for the next budget year.

# Dossier include the following

## Part I - Synopsis

- Form A - Product and company information
- Form B - Price declaration
- MoH approved prescribing information if available
- Executive summary of part II

## Part II - Clinical Information

- The disease and its treatment
- Unmet need
- The active substance, ATC, mechanism of action
- The rationale of using the product for this condition.
- Treatments protocol
- Where is the product administered: home, clinic, hospital
- Summary of published clinical trials, posters, abstract and analysis
- Alternative treatments/competitors
- Advantages of the submitted product over its competitors
- Treatment Algorithm - product line of treatment
- Guidelines recommending the product
- Global data: authorization, reimbursement, prices worldwide,
- Safety information: adverse events, warnings, contraindication, risk management program
- Local experience with the product: sales, compassionate use, clinical trials
- Global experience with the product: sales, compassionate use, clinical trials
- The product expected future indications
- Physicians' recommendation letter

## Part III - Epidemiology

- Global and local information re disease prevalence and incidence
- Market size
- Expected market share
- Expected growth of the market size for the next 3 years
- Expected growth of the market share for the next 3 years

## Part IV - Economic evaluation and Budget impact